J&J also lowered its full-year adjusted operational EPS guidance as a result of costs associated with recent strategic acquisitions that 'more than offset the improvement.'
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,